Free shipping over €250 · Tracked, discreet delivery in Europe
UU library
Every peptide, mapped to the body.
160 compounds, from approved medicines to early research molecules. Each one filed by the system research looks at, with its regulatory status and the strength of the evidence behind it.
- Compounds
- 160
- Research summaries
- 39
- At UU
- 56
- Approved medicine71
Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.
- In clinical trials19
In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.
- Research compound53
Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.
- Cosmetic ingredient17
Used as a topical cosmetic ingredient. Cosmetic use is not a medicinal approval, and most evidence comes from manufacturer and small panel studies.
Reviewed October 2026
In the UU catalog
Researched, batch-tested, ready to ship.
Compounds UU carries that have a full research summary in the library.
18 compounds · Sexual & reproductive
Sexual & reproductive18
Melanocortins, kisspeptin, oxytocin and the GnRH analogues of reproductive medicine.
- ResearchAt UU
Kisspeptin-10
Kisspeptin receptor agonist
The shortest active fragment of kisspeptin, the upstream signal for GnRH. Studied in human physiology research on reproductive hormones.
Early human dataShop - Approved
Atosiban
Tractocile
Oxytocin receptor antagonist
An oxytocin antagonist approved in Europe to delay imminent preterm birth.
Summary pending - Approved
Cetrorelix
Cetrotide
GnRH antagonist
A GnRH antagonist approved to block premature ovulation during controlled ovarian stimulation in IVF.
Summary pending - Approved
Degarelix
Firmagon
GnRH antagonist
A GnRH antagonist approved for advanced prostate cancer.
Summary pending - Approved
Ganirelix
GnRH antagonist
A GnRH antagonist approved to block the premature LH surge during IVF.
Summary pending - Approved
Gonadorelin
GnRH · Factrel
GnRH
Synthetic gonadotropin-releasing hormone. Approved as a diagnostic agent for pituitary function.
Summary pending - Approved
Goserelin
Zoladex
GnRH agonist
A GnRH agonist given as an implant. Approved for prostate cancer, breast cancer and endometriosis.
Summary pending - Approved
Histrelin
Supprelin LA · Vantas
GnRH agonist
A GnRH agonist given as a yearly implant. Approved for central precocious puberty.
Summary pending - Approved
Human chorionic gonadotropin
hCG · Pregnyl
Glycoprotein hormone
The pregnancy hormone, a glycoprotein that acts at LH receptors. Approved to trigger ovulation and for some forms of hypogonadism.
Summary pending - Approved
Leuprolide
Leuprorelin · Lupron
GnRH agonist
A GnRH agonist approved for prostate cancer, endometriosis and central precocious puberty.
Summary pending - Research
Melanotan II
MT-II
Melanocortin agonist
A cyclic, non-selective melanocortin agonist never approved as a medicine. Studied for pigmentation, and the parent compound of bremelanotide.
Summary pending - Approved
Nafarelin
Synarel
GnRH agonist
A nasal GnRH agonist approved for endometriosis and central precocious puberty.
Summary pending - Approved
Triptorelin
Trelstar · Decapeptyl
GnRH agonist
A GnRH agonist approved for advanced prostate cancer and, in some markets, other hormone-dependent conditions.
Summary pending
The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.